Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 12
2003 14
2004 16
2005 16
2006 18
2007 28
2008 36
2009 43
2010 36
2011 41
2012 53
2013 67
2014 62
2015 56
2016 44
2017 89
2018 89
2019 117
2020 137
2021 146
2022 160
2023 144
2024 79

Text availability

Article attribute

Article type

Publication date

Search Results

1,351 results

Results by year

Filters applied: . Clear all
Page 1
Patient-Derived Organoids Can Guide Personalized-Therapies for Patients with Advanced Breast Cancer.
Chen P, Zhang X, Ding R, Yang L, Lyu X, Zeng J, Lei JH, Wang L, Bi J, Shao N, Shu D, Wu B, Wu J, Yang Z, Wang H, Wang B, Xiong K, Lu Y, Fu S, Choi TK, Lon NW, Zhang A, Tang D, Quan Y, Meng Y, Miao K, Sun H, Zhao M, Bao J, Zhang L, Xu X, Shi Y, Lin Y, Deng C. Chen P, et al. Among authors: lin y. Adv Sci (Weinh). 2021 Nov;8(22):e2101176. doi: 10.1002/advs.202101176. Epub 2021 Oct 4. Adv Sci (Weinh). 2021. PMID: 34605222 Free PMC article.
BRCA1 Insufficiency Induces a Hypersialylated Acidic Tumor Microenvironment That Promotes Metastasis and Immunotherapy Resistance.
Shu X, Li J, Chan UI, Su SM, Shi C, Zhang X, An T, Xu J, Mo L, Liu J, Wang Y, Li X, Deng M, Lei JH, Wang C, Tian H, Heng S, Shim JS, Zhang X, Dai Y, Yao Z, Kuang X, Lin Y, Deng CX, Xu X. Shu X, et al. Among authors: lin y. Cancer Res. 2023 Aug 1;83(15):2614-2633. doi: 10.1158/0008-5472.CAN-22-3398. Cancer Res. 2023. PMID: 37227919 Free PMC article.
Longitudinal MRI-based fusion novel model predicts pathological complete response in breast cancer treated with neoadjuvant chemotherapy: a multicenter, retrospective study.
Huang Y, Zhu T, Zhang X, Li W, Zheng X, Cheng M, Ji F, Zhang L, Yang C, Wu Z, Ye G, Lin Y, Wang K. Huang Y, et al. Among authors: lin y. EClinicalMedicine. 2023 Mar 24;58:101899. doi: 10.1016/j.eclinm.2023.101899. eCollection 2023 Apr. EClinicalMedicine. 2023. PMID: 37007742 Free PMC article.
Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative, early-stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open-label phase II trial.
Zhang L, Wu ZY, Li J, Lin Y, Liu Z, Cao Y, Zhang G, Gao HF, Yang M, Yang CQ, Zhu T, Cheng MY, Ji F, Li J, Wang K. Zhang L, et al. Among authors: lin y. Int J Cancer. 2022 Feb 15;150(4):654-662. doi: 10.1002/ijc.33830. Epub 2021 Oct 7. Int J Cancer. 2022. PMID: 34591977 Free article. Clinical Trial.
1,351 results